Bellus hit with a setback as its PhII chronic cough drug flops on all 4 doses — shares cremated on Wall Street
Bellus Health says their Phase II study for a new drug to treat chronic cough failed, but they already lined up Plan B to help ease the sting with investors.
The biotech tested 4 different doses of BLU-5937 in the mid-stage study, all of which fell short of the mark for placebo-adjusted reductions in coughing — several by a wide margin. It also didn’t help that there was no clear dose response in the mix, with a jumble of outcomes to report. Bellus $BLU immediately tried to shift focus to a silver lining, noting that they hit statistical significance among a subgroup of “high cough count patients (all patients at or above the baseline median average of 32.4 coughs per hour).”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.